Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer

Author:

Forouhi P1,Dixon J M1,Leonard R C F1,Chetty U1

Affiliation:

1. The Edinburgh Breast Unit, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK

Abstract

Abstract The influence of primary systemic therapy in treating operable breast cancer on postmastectomy morbidity rates was investigated. The contribution of other risk factors was assessed by multiple logistic regression. Seventy-nine eligible patients were randomly allocated, 39 to undergo immediate modified radical mastectomy, and 40 to receive initial cytotoxic or endocrine treatment followed by mastectomy. Postoperative wound seroma, infection and necrosis were recorded prospectively. Fourteen minor and six major complications occurred in 17 patients treated conventionally, while 14 patients developed 11 minor and six major complications after systemic therapy (P >0·4). Median hospital stay was 8 days for both groups. Age, smoking, immediate breast reconstruction and the type of primary systemic treatment given were not independent predictors of complication risk. Obesity emerged as a significant risk factor for postmastectomy complications (P = 0·015). Primary systemic therapy does not increase the rate of morbidity after mastectomy.

Funder

Scottish Hospitals Endowments Research Trust

Publisher

Oxford University Press (OUP)

Subject

Surgery

Reference38 articles.

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women;Early Breast Cancer Trialists' Collaborative Group;Lancet,1992

2. A pharmacological rationale for neoadjuvant chemotherapy with Adriamycin in locally advanced breast cancer;Gasparini;Anticancer Res,1990

3. Experimental basis and clinical reality of preoperative (neoadjuvant) chemotherapy in breast cancer;Ragaz;Recent Results Cancer Res,1989

4. Primary chemotherapy can avoid mastectomy, but there is more to it than that;DeVita;J Natl Cancer Inst,1990

5. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy;Goldie;Semin Oncol,1987

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3